Hudson Bay Capital Management
BNTC icon

Hudson Bay Capital Management’s Benitec Biopharma BNTC Stock Holding History

Hudson Bay Capital Management’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,353
Closed -$324K – 864
2020
Q4 		$324K Buy
+6,353
New +$316K ﹤0.01% 517

Other funds holding BNTC

HAG
HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Hudson Bay Capital Management's BNTC Position: Q1 2021 in Review

Hudson Bay Capital Management sold out of Benitec Biopharma (BNTC) in Q1 2021, closing a stake of 6,353 shares — an estimated $324K sold.

Hudson Bay Capital Management first reported a position in BNTC in Q4 2020 and held it in 1 quarter. The position peaked at $324K in Q4 2020. 14 funds tracked by Wall St. Rank hold BNTC as of Q1 2021.

  • Hudson Bay Capital Management reported no remaining Benitec Biopharma position as of Q1 2021 after selling out during the quarter.
  • Hudson Bay Capital Management sold 6,353 Benitec Biopharma shares in Q1 2021, an estimated $324K.
  • Hudson Bay Capital Management first reported a position in Benitec Biopharma in Q4 2020 and held it in 1 quarter.
  • Hudson Bay Capital Management's Benitec Biopharma position peaked at $324K in Q4 2020.
  • 14 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2021.

Based on Hudson Bay Capital Management's 13F filing for Q1 2021, filed 14 May 2021.